DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration

CENTER FOR DRUG EVALUATION AND RESEARCH

Office of Manufacturing and Product Quality
Division International Drug Quality
International Compliance Branch
10903 New Hampshire Avenue
Building #51, Room 4221
Silver Spring, MD 20993

TELEPHONE: (301) 796-3916
FAX: (301) 847-8742

May 16, 2013

Mr. loan Nani
President and Chairman of the Board of Directors
Antibiotice S.A.
No.1, Valea Lupului Street
Iasi,
Romania

Reference: FEI 3003489017

Dear Mr. Nani:

We have completed our review of the Establishment Inspection Report (EIR) for the inspection conducted at your manufacturing facility in Iasi, Romania by Investigator Charles Cote during the period of January 14-22, 2013.

Based on the profile class covered during the inspection, we are classifying your facility as acceptable. This letter is not intended as an endorsement or certification of the facility. It remains your responsibility to assure continued compliance with current good manufacturing practice (CGMP).

Please be advised that all manufacturers must register annually as required by 21 C.F.R. § 207.40. Information on how to register is available at **http://www.fda.gov/cder/drls/registration_listing.htm**

Additionally, we enclose a copy of the establishment inspection report (EIR). Releasing this EIR to you is part of FDA's effort to make its regulatory process and activities more transparent to the regulated industry. It is being provided to you for information purposes only and may reflect some redactions made by the Agency in accordance with the Freedom of Information Act and 21 C.F.R. Part 20. Copies provided to other requestors may have additional redactions of trade secret and confidential commercial information.

If you have any questions regarding this letter, you may contact me at the above address or number.

Sincerely,

Maan Abduldayem
Compliance Officer
Division of International Drug Quality

Enclosure: EIR